NRx Pharmaceuticals (NRXP) Announces Data-Lock of Phase 2b/3

NRx Pharmaceuticals (NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

NRx Pharmaceuticals (NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Massachusetts , United States , Jonathan Javitt , Andrew Nierenberg , Nrx Pharmaceuticals , Alvogen Inc , Nrx Pharmaceuticals Inc , Nasdaq , Nrxp Nrx Pharmaceuticals , Lotus Pharmaceuticals Inc , Treatment Resistant Bipolar Depression Study , Lotus Pharmaceuticals , Breakthrough Therapy Designation , Fast Track Designation , Biomarker Letter , Special Protocol Agreement , Suicidal Treatment Resistant Bipolar , Severe Bipolar Depression , Acute Suicidal Ideation , Special Protocol , New Drug , Chief Scientist , New Drug Application , Principal Investigator , Harvard Massachusetts General , Montgomery Asberg Depression Rating Scale , Clinical Global Impression Suicidality Scale ,